Mechanism of action of licensed vaccine adjuvants

被引：145

作者：

Tritto, Elaine ^{[1
]}

Mosca, Flaviana ^{[1
]}

De Gregorio, Ennio ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost, I-53100 Siena, Italy

来源：

VACCINE | 2009年 / 27卷 / 25-26期

关键词：

Innate immunity; Alum; MF59; NLRP3; inflammasome; ALUMINUM-HYDROXIDE; DENDRITIC CELLS; NALP3; INFLAMMASOME; INTRAMUSCULAR INJECTION; INFLUENZA VACCINE; RESPONSES; MF59; ANTIBODY; MICE; DIFFERENTIATION;

D O I：

10.1016/j.vaccine.2009.01.084

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Despite the fact that alum and oil-in-water emulsions have been used for decades as human vaccine adjuvants in a large number of individuals, their mechanism of action is not completely understood. It has been reported that these particulate adjuvants act by increasing antigen availability and uptake by immune cells. However, recent work on alum and on the squalene-based emulsion MF59, has demonstrated that besides antigen delivery functions, these classes of adjuvants can also activate innate immunity pathways in vivo, generating an immunocompetent environment at injection site. Interestingly, it has been demonstrated that alum adjuvanticity depends on the activation of a protein complex called NLPR3/inflammasome, which is required for the correct processing of a number of pro-inflammatory cytokines, including IL1 beta. More work needs to be performed to investigate if the inflammasome is also required for the activity of MF59 and of other particulate vaccine adjuvants. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：3331 / 3334

页数：4

共 31 条

[1] Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations [J].